PTCT

43.23

0.79% 0.34

Handel nachbörslich: 43.23

Ptc Therapeutics Inc (PTCT)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt PTCT? Forum Prognose

Schlusskurs vom Vortag:

$42.89

Offen:

$43.03

24-Stunden-Volumen:

541.83K

Relative Volume:

0.80

Marktkapitalisierung:

$3.30B

Einnahmen:

$900.45M

Nettoeinkommen (Verlust:

$-479.52M

KGV:

-4.9977

EPS:

-8.65

Netto-Cashflow:

$-230.14M

1W Leistung:

+10.20%

1M Leistung:

+9.94%

6M Leistung:

+11.88%

1J Leistung:

+99.95%

1-Tages-Spanne:

$42.74

$44.10

1-Wochen-Bereich:

$38.26

$44.10

52-Wochen-Spanne:

$20.75

$46.98

Ptc Therapeutics Inc Stock (PTCT) Company Profile

Firmenname

Ptc Therapeutics Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

(908) 222-7000

Adresse

500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ

Mitarbeiter

Twitter

@PTCBio

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

PTCT's Discussions on Twitter

Vergleichen Sie PTCT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PTCT	43.23	3.30B	900.45M	-479.52M	-230.14M	-8.65
VRTX	450.97	116.14B	10.63B	-479.80M	-1.35B	13.33
REGN	738.00	81.10B	13.85B	4.65B	3.32B	35.06
ARGX	605.92	36.23B	1.86B	-40.29M	-1.28B	-4.16
ALNY	244.89	31.59B	2.09B	-332.26M	16.06M	-4.14
BNTX	113.13	27.12B	3.30B	-501.07M	1.03B	11.54

Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-19	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-10-30	Hochstufung	Oppenheimer	Perform → Outperform
2023-10-27	Herabstufung	Citigroup	Neutral → Sell
2023-10-06	Herabstufung	Truist	Buy → Hold
2023-09-18	Herabstufung	Citigroup	Buy → Neutral
2023-09-15	Herabstufung	Raymond James	Outperform → Underperform
2023-03-17	Eingeleitet	SVB Securities	Market Perform
2022-12-14	Eingeleitet	Goldman	Sell
2022-09-12	Eingeleitet	Jefferies	Buy
2022-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2022-09-01	Eingeleitet	Citigroup	Buy
2022-04-04	Fortgesetzt	Cantor Fitzgerald	Overweight
2021-10-18	Herabstufung	BofA Securities	Neutral → Underperform
2021-04-26	Fortgesetzt	Credit Suisse	Neutral
2021-03-29	Hochstufung	RBC Capital Mkts	Underperform → Sector Perform
2021-02-12	Herabstufung	BofA Securities	Buy → Neutral
2021-01-05	Hochstufung	Citigroup	Neutral → Buy
2020-11-30	Herabstufung	RBC Capital Mkts	Sector Perform → Underperform
2020-10-30	Herabstufung	Citigroup	Buy → Neutral
2020-10-28	Eingeleitet	UBS	Neutral
2020-10-07	Hochstufung	JP Morgan	Neutral → Overweight
2020-08-25	Eingeleitet	Raymond James	Outperform
2020-04-09	Hochstufung	Citigroup	Neutral → Buy
2020-02-20	Herabstufung	Citigroup	Buy → Neutral
2020-02-20	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2019-11-12	Eingeleitet	SunTrust	Buy
2019-05-13	Hochstufung	BofA/Merrill	Neutral → Buy
2019-04-11	Eingeleitet	Bernstein	Outperform
2018-10-03	Hochstufung	BofA/Merrill	Underperform → Neutral
2018-10-01	Eingeleitet	Cantor Fitzgerald	Overweight
2018-07-19	Eingeleitet	Credit Suisse	Outperform
2018-06-18	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2018-04-04	Herabstufung	Barclays	Equal Weight → Underweight
2018-01-29	Fortgesetzt	RBC Capital Mkts	Sector Perform
2017-11-16	Hochstufung	JP Morgan	Underweight → Neutral
2017-10-26	Herabstufung	BofA/Merrill	Neutral → Underperform
2017-10-09	Herabstufung	JP Morgan	Neutral → Underweight

Alle ansehen

Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten

Nov 22, 2024

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Quest Partners LLC - MarketBeat

Nov 22, 2024

Nov 20, 2024

Phenylketonuria Market size is ~700 USD million in 2023, asserts DelveInsight | Pharma Giants: PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals - The Globe and Mail

Nov 20, 2024

PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN

Nov 20, 2024

Nov 19, 2024

ARMISTICE CAPITAL, LLC Acquires Additional Shares in PTC Therape - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

PTC Therapeutics wins FDA nod for gene therapy - MSN

Nov 14, 2024

PTC Gets US FDA Approval For Brain-Delivered Gene Therapy - News & Insights

Nov 14, 2024

PTC Therapeutics Wins First FDA Approval for a Gene Therapy Dosed Directly Into the Brain - MedCity News

Nov 14, 2024

FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain - AOL

Nov 14, 2024

PTC Therapeutics' Gene Therapy For AADC Deficiency Approved By FDA - Contract Pharma

Nov 14, 2024

AADC deficiency gene therapy, called Kebilidi, now approved in US - AADC News

Nov 14, 2024

FDA Approves Eladocagene Exuparvovec-Tneq for Treatment of AADC Deficiency - Pharmacy Times

Nov 14, 2024

PTC wins US approval of gene therapy for fatal enzyme disorder - BioPharma Dive

Nov 14, 2024

PRV sweetens PTC approval of Kebilidi in AADC deficiency - BioWorld Online

Nov 14, 2024

FDA grants accelerated approval for PTC’s AADC deficiency gene therapy - Yahoo Finance

Nov 14, 2024

FDA nod for AADC deficiency gene therapy from PTC - The Pharma Letter

Nov 14, 2024

PTC Therapeutics wins FDA nod for gene therapy (PTCT:NASDAQ) - Seeking Alpha

Nov 14, 2024

PTC Wins First FDA Nod for Direct-to-Brain Gene Therapy, Targets Ultrarare Disease - BioSpace

Nov 14, 2024

PTC gets FDA okay for first brain-delivered gene therapy - pharmaphorum

Nov 14, 2024

Nov 13, 2024

PTC Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder - Reuters.com

Nov 13, 2024

PTC Therapeutics Wins FDA Approval for Groundbreaking Brain Gene Therapy KEBILIDI | PTCT Stock News - StockTitan

Nov 13, 2024

PTC Therapeutics's SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com

Nov 13, 2024

Nov 11, 2024

Barclays Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price - MarketBeat

Nov 11, 2024

Nov 09, 2024

PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

PTC Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 09, 2024

PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $40.38 Average Target Price from Analysts - MarketBeat

Nov 09, 2024